<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antisocial personality disorder: Treatment overview</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antisocial personality disorder: Treatment overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antisocial personality disorder: Treatment overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald W Black, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Skodol, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H19520647"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Antisocial personality disorder (ASPD) is defined as a pattern of socially irresponsible, exploitative, and guiltless behavior. ASPD is a lifelong disorder that typically begins in childhood or early adolescence, is fully manifest by the late 20s or early 30s, and is associated with disturbances in many areas of life [<a href="#rid1">1,2</a>].</p><p>Typical behaviors include criminality, failure to sustain consistent employment, exploitation of others for personal gain, and failure to develop stable interpersonal relationships. Other features of ASPD include lacking empathy for others, rarely experiencing remorse, and failing to learn from the negative results of one’s experiences [<a href="#rid3">3,4</a>].</p><p>This topic describes treatment for ASPD. Other aspects of ASPD are discussed separately. Pharmacotherapy for personality disorders is reviewed separately. (See  <a class="medical medical_review" href="/d/html/14760.html" rel="external">"Antisocial personality disorder: Epidemiology, clinical manifestations, course, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/108263.html" rel="external">"Personality disorders: Overview of pharmacotherapy"</a>.)</p><p class="headingAnchor" id="H1246994902"><span class="h1">TREATMENT OF ANTISOCIAL PERSONALITY DISORDER</span><span class="headingEndMark"> — </span>Individuals with antisocial personality disorder (ASPD) typically present seeking treatment for symptoms related to a comorbid disorder (eg, mood dysregulation, substance use) or due to problematic psychosocial stressors (eg, work, relationship, legal) [<a href="#rid5">5-7</a>]. For individuals willing to engage in treatment, our preference for treatment modality is based on symptom severity, the presence of aggressive behaviors, and the presence of co-occurring disorders. Our preferred treatment of ASPD is presented in the algorithm (<a class="graphic graphic_algorithm graphicRef139302" href="/d/graphic/139302.html" rel="external">algorithm 1</a>). (See <a class="local">'ASPD with comorbid disorders'</a> below and <a class="local">'Mild or moderate ASPD'</a> below and <a class="local">'Individuals with aggressive behavior'</a> below and <a class="local">'Severe ASPD (psychopathy)'</a> below.)</p><p class="headingAnchor" id="H1436323602"><span class="h2">ASPD with comorbid disorders</span><span class="headingEndMark"> — </span>We address comorbid disorders (eg, mood disorders, substance use disorders [SUDs], attention deficit hyperactivity disorder) as a first step in the treatment of individuals with ASPD. We address the comorbid disorders according to their preferred treatment method; however, we avoid treatment with medications that have an increased risk of misuse or dependence (see <a class="local">'Medications to avoid'</a> below). Limited evidence suggests that patients with personality disorders (including ASPD) treated for comorbid disorders such as depression do not respond as well to treatment as do persons without a personality disorder [<a href="#rid8">8</a>]. In our experience, successful treatment of comorbid disorder may lead to improvement of the symptoms of ASPD or improved response to treatment for ASPD.</p><p class="headingAnchor" id="H1258868596"><span class="h3">Substance use disorders</span><span class="headingEndMark"> — </span>We treat individuals with ASPD and co-occurring SUD with medical management of withdrawal when indicated. We follow this with inpatient or outpatient psychosocial addiction programs such as Alcoholics Anonymous or Narcotics Anonymous with a goal of abstinence.</p><p>While treatment of SUDs can be challenging, benefits may extend to ASPD as well as SUD. In a study of individuals with ASPD and comorbid SUD, individuals who were treated with <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance were less likely to engage in antisocial or criminal behaviors, had fewer family conflicts and fewer emotional problems than those who continued to engage in substance misuse [<a href="#rid9">9</a>].</p><p>There are few studies of treatment of co-occurring SUDs with ASPD. These studies have largely showed similar outcomes between study group and control [<a href="#rid10">10,11</a>].</p><p>As examples, in two separate trials of contingency management for SUD co-occurring with ASPD, active treatment with contingency management did not demonstrate a benefit over treatment as usual. (See  <a class="medical medical_review" href="/d/html/103550.html" rel="external">"Substance use disorders: Training, implementation, and efficacy of treatment with contingency management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a clinical trial, 40 patients with ASPD and SUD were randomly assigned to receive either a structured contingency management intervention in addition to standard SUD treatment, or to standard SUD treatment alone [<a href="#rid10">10</a>]. Improvement was seen in both groups over 17 weeks of treatment, but no significant differences were seen between groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another clinical trial, 100 patients with opioid dependence and ASPD were randomly assigned to a structured contingency management intervention plus <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance or to methadone maintenance alone [<a href="#rid11">11</a>]. No differences were seen between intervention groups in drug abstinence. The group receiving the contingency management had better attendance than subjects receiving methadone maintenance alone.</p><p></p><p>Management of specific SUDs are described separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7800.html" rel="external">"Alcohol use disorder: Pharmacologic management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16753.html" rel="external">"Substance use disorders: Psychosocial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106878.html" rel="external">"Stimulant use disorder: Treatment overview"</a>.)</p><p></p><p class="headingAnchor" id="H2678990468"><span class="h3">Comorbid borderline personality disorder</span><span class="headingEndMark"> — </span>Psychotherapy with efficacy in specified disorders, such as borderline personality disorder, appears to remain effective when the disorders co-occur with ASPD:</p><p class="bulletIndent1"><span class="glyph">●</span>In two uncontrolled cohorts of 64 and 65 patients, co-occurring ASPD did not appear to interfere with the efficacy of Systems Training for Emotional Predictability and Problems Solving group therapy for borderline personality disorder [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A clinical trial randomly assigned 40 patients with co-occurring borderline personality disorder and ASPD to receive mentalization-based therapy or structured clinical management [<a href="#rid13">13</a>]. After treatment for 18 months, both groups showed overall symptom improvement, but patients assigned to mentalization-based therapy had greater improvement in anger, hostility, paranoia, and suicidal and self-harm behaviors than those in structured clinical management. (See  <a class="medical medical_review" href="/d/html/6618.html" rel="external">"Borderline personality disorder: Psychotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an uncontrolled trial in a correctional setting, 30 males with co-occurring borderline personality disorder and antisocial behavior received 12 months of dialectical behavior therapy and were then followed for one year. Reductions in self-harm, verbal and physical aggression, and criminal reoffending, as well as symptoms of borderline personality disorder were noted [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H1635673797"><span class="h2">Mild or moderate ASPD</span><span class="headingEndMark"> — </span>We suggest cognitive-behavioral therapy (CBT) as the initial treatment for individuals with mild or moderate ASPD. While the results of most clinical trials evaluating CBT for persons with ASPD have not demonstrated clear efficacy, it is possible that CBT may benefit those with milder forms of the disorder and those who possess some insight or have reason to improve (eg, individuals who risk losing a spouse or job due to their behavior) [<a href="#rid15">15</a>]. (See <a class="local">'Efficacy of CBT'</a> below.)</p><p class="headingAnchor" id="H1675378292"><span class="h3">Focus and goals of CBT</span><span class="headingEndMark"> — </span>We set guidelines for the patient’s involvement in the treatment of individuals with ASPD. These include attendance, active participation, and completion of homework outside of office visits [<a href="#rid16">16</a>]. We do this to enhance engagement in the treatment and patient accountability.</p><p>Using CBT, we focus on the patient’s beliefs about themselves or others and behaviors that impair social functioning [<a href="#rid17">17</a>]. Our preference is to focus on evaluating situations in which the patient’s distorted beliefs and attitudes may have interfered with interpersonal functioning or in achieving goals. Once the patient has gained an understanding of how they have contributed to the problematic situation, we assist them in gradually making changes to their thinking and behavior. For example, cognitive distortions underlying the patient’s thinking and behavior can be challenged such as the belief that they can do no wrong, or that feelings justify actions.</p><p>Throughout the treatment, we aim to be aware of our feelings and remain vigilant to prevent them from disrupting the therapy (eg, through countertransference) [<a href="#rid18">18</a>]. Individuals with ASPD often possess traits that actively interfere with the process of psychotherapy and make working with them difficult (eg, impulsivity, blaming others) [<a href="#rid4">4</a>]. Additionally, the individual’s criminal past, tendency towards violence, and irresponsibility may affect the therapist’s feelings towards them. Many providers find it difficult, if not impossible, to work with individuals with these traits.</p><p>Mental health professionals experienced in treating ASPD who are able to anticipate their emotions, present an attitude of acceptance tempered with limit setting, and confront problematic behaviors without moralizing, provide the best prospects for treatment [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H3751830823"><span class="h3">Efficacy of CBT</span><span class="headingEndMark"> — </span>Trials for treatment of ASPD with CBT have not consistently supported any psychological intervention [<a href="#rid19">19,20</a>]. In one trial, 52 men with ASPD and recent aggression were randomly to receive CBT plus treatment as usual or treatment as usual alone [<a href="#rid20">20</a>]. At 12 months, both groups demonstrated similar declines in the number of reported aggressive acts (physical and verbal). Trends in favor of CBT were seen for problematic drinking, social functioning, and developing more positive beliefs about others. Other data suggest a role for CBT in the treatment of ASPD; however, larger randomized trials may demonstrate more robust evidence of efficacy [<a href="#rid21">21,22</a>].</p><p>CBT may be useful in the treatment of some disorders that co-occur with ASPD. (See <a class="local">'ASPD with comorbid disorders'</a> above.)</p><p class="headingAnchor" id="H426321216"><span class="h3">Adjunctive psychosocial interventions</span><span class="headingEndMark"> — </span>We use these interventions in addition to CBT for individuals with limited response to CBT or in cases with specific stressors (ie, marital discord). Limited data support their use.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychoeducation</strong> – A subgroup analysis of a trial of psychoeducation and problem-solving therapy for personality disorders did not find evidence of efficacy for ASPD [<a href="#rid23">23</a>]. Twenty-four patients with ASPD were randomly assigned to receive either brief psychoeducation (eg, education about personality disorders and their potential effects on psychosocial functioning) plus problem-solving group sessions or to a waiting list with treatment as usual. After an average of 24 weeks, no difference was seen between groups on measures of problem solving or social functioning.</p><p></p><p class="bulletIndent1">A clinical trial comparing a short-term psychoeducational program with treatment as usual in 175 people with ASPD receiving treatment for an SUD found that the program improved adherence to SUD treatment [<a href="#rid24">24</a>]. The direct effects of the program on abstinence and ASPD behaviors were not reported. However, a post-hoc secondary analysis found that the program increased the subject’s sense of having received help for their ASPD, which was associated with more days abstinent, fewer treatment drop outs, and increased treatment satisfaction with regard to their comorbid SUD [<a href="#rid25">25</a>]. The six-session program was designed to address impulsive and self-destructive behaviors associated with ASPD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Marital/family therapy</strong> – In individuals whose symptoms have been disruptive to their families, or other committed relationships, we suggest family or marital therapy. We try to engage the family members in order help them gain a better understanding of how the disorder has impacted the relationship. Additionally, it is helpful for family members to receive guidance about their interactions with their relative with ASPD. Couples therapy will not be beneficial if the antisocial person is disruptive or lacks empathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schema therapy and contingency management </strong>– Small, randomized trials including individuals with ASPD appear to show improved social functioning with schema therapy and contingency management compared with treatment as usual, and reduced number of harm days with dialectical behavior therapy compared with treatment as usual [<a href="#rid26">26</a>]. The evidence in each case was of low certainty.</p><p></p><p class="bulletIndent1">Schema therapy and contingency management are discussed separately. (See  <a class="medical medical_review" href="/d/html/6618.html" rel="external">"Borderline personality disorder: Psychotherapy", section on 'Schema-focused therapy'</a> and  <a class="medical medical_review" href="/d/html/14849.html" rel="external">"Substance use disorders: Principles, components, and monitoring during treatment with contingency management"</a>.)</p><p></p><p class="headingAnchor" id="H1389923867"><span class="h2">Severe ASPD (psychopathy)</span><span class="headingEndMark"> — </span>We do not treat individuals who have high levels of ASPD pathology (eg, psychopathy) with psychotherapy. Rather, when present, we address comorbid disorders (eg, depression, anxiety) with pharmacotherapy according to the recommended guidelines for the disorder. We address aggressive behaviors with pharmacotherapy. (See <a class="local">'ASPD with comorbid disorders'</a> above and <a class="local">'Individuals with aggressive behavior'</a> below.)</p><p>Psychotherapy may be ineffective or even harmful when provided to persons with psychopathy or severe ASPD [<a href="#rid27">27,28</a>]. One perspective is that the rigid personality structure of these individuals generally resists outside influence [<a href="#rid27">27</a>], observing that in therapy, many often simply go through the motions, and may even learn skills that help them better influence or exploit others. This concern is particularly pronounced for group therapy.</p><p>Psychopathy is described separately. (See  <a class="medical medical_review" href="/d/html/14760.html" rel="external">"Antisocial personality disorder: Epidemiology, clinical manifestations, course, and diagnosis", section on 'Psychopathy'</a>.)</p><p class="headingAnchor" id="H3444167099"><span class="h2">Individuals with aggressive behavior</span><span class="headingEndMark"> — </span>We treat individuals with ASPD (including those with severe ASPD) and aggressive behavior with medications. </p><p class="headingAnchor" id="H4010618680"><span class="h3">Indications for medication treatment</span><span class="headingEndMark"> — </span>Aggressive behavior, which can be prominent in some patients with ASPD, may be a target symptom of daily medication treatment. The decision to treat aggression with medication in patients with ASPD should be based upon:</p><p class="bulletIndent1"><span class="glyph">●</span>The severity of symptoms with respect to impairing the individual’s ability to function in their environment (eg, in the community or in an institutional setting)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient’s willingness to take the medication</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The availability of a clinician to monitor treatment and evaluate its effectiveness</p><p></p><p>Limited data support the use of pharmacologic management in the treatment of aggressive behavior in individuals with ASPD [<a href="#rid15">15,29,30</a>]. In a meta-analysis, there was insufficient evidence supporting the use of any single pharmacologic intervention in the treatment of aggression in ASPD; however, small trials and cases reports suggest that several medication may be useful reducing aggressive behavior in samples of individuals associated with higher rates of ASPD (eg, prisoners, individuals with a history of aggression, children with conduct disorder) [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H866340388"><span class="h3">Antipsychotics as first choice for aggression</span><span class="headingEndMark"> — </span>We treat individuals with aggression in the context of ASPD with second-generation antipsychotic medications as our first choice. Our preference comes from our clinical experience and case reports [<a href="#rid31">31,32</a>]. We prefer to use second-generation antipsychotics due to their sedative properties and for some agents, their favorable side effect profile. There are no randomized trials of antipsychotic medications for aggressive behavior in patients with ASPD. (See  <a class="medical medical_review" href="/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a>.)</p><p>We treat individuals with aggressive behavior in the context of ASPD with doses of antipsychotics towards the lower end of the therapeutic range. In our experience, a lower dose can be useful in lessening aggressive behaviors while minimizing the risk of adverse effects.</p><p>As examples, we begin <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> at 1 mg per day and titrate by 1 mg each week to a total of 3 to 4 mg of risperidone daily. We then wait for a full 8 to 12 weeks and monitor behavior. For individuals with ongoing aggressive behavior, we continue to titrate the medication by 1 mg per week towards 6 mg per day (upper end of the usual dose range).</p><p><a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">Quetiapine</a> is a reasonable alternative to <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>; we initiate treatment at 25 mg and titrate by 25 mg per week to 100 mg/day. We then wait a full 8 to 12 weeks to monitor behavior prior to further increases. We typically then titrate by 50 mg per week to 150 to 200 mg per day. It is rarely necessary to go to higher doses, such as may be used in schizophrenia.</p><p>In all individuals treated with second-generation antipsychotic medications we monitor for side effects and metabolic dysregulation at regular intervals. (See  <a class="medical medical_review" href="/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Monitoring'</a>.)</p><p>For individuals who tolerate and respond adequately to antipsychotic treatment (eg, less aggressive behavior), we continue medications indefinitely while monitoring for side effects on a regular basis (see  <a class="medical medical_review" href="/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>). There are no randomized trials of antipsychotic medications for aggressive behavior in patients with ASPD; however, case reports suggest that these drugs may be useful [<a href="#rid31">31,32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A case series of four patients with ASPD and aggressive behavior, found that voluntary treatment with <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> (typical dose 600 to 800 mg/day) was associated with decreased irritability, impulsivity, and aggressiveness [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one case report, a 32-year-old man with ASPD was successfully treated with <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> for severe violent behavior [<a href="#rid32">32</a>]. He was initially treated with 6 mg/day and developed extrapyramidal symptoms that required treatment with biperiden, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, and <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>. He continued treatment on a maintenance dose of risperidone 3 mg/day.</p><p></p><p>Adverse effects of second-generation antipsychotics include extrapyramidal symptoms, weight gain, and metabolic syndrome. (See  <a class="medical medical_review" href="/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Side effect management'</a>.)</p><p class="headingAnchor" id="H4032277846"><span class="h3">Subsequent treatment for inadequate response</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trial of another second-generation antipsychotic medication</strong> – For individuals who do not respond adequately to treatment with a second-generation antipsychotic medication, our preference is to try another second-generation antipsychotic rather than another class of medications. Individuals who do not respond to one antipsychotic may respond favorably to another antipsychotic. Our preference is to taper off of the first antipsychotic then start the second antipsychotic at a low dose and titrate while monitoring for effect. (See <a class="local">'Antipsychotics as first choice for aggression'</a> above.)</p><p></p><p class="bulletIndent1">For individuals who do not respond to two antipsychotics our preference for further pharmacologic management is discussed below. For individuals with ASPD our preference is to try medications sequentially to avoid polypharmacy. Limited data support the efficacy of these treatments for aggression in individuals with ASPD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selective serotonin reuptake inhibitors (SSRIs)</strong> – We use SSRIs for aggressive behavior in ASPD according to guidelines used for the treatment of depression. We typically begin <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> at 50 mg and titrate by 50 mg per week to 150 to 200 mg per day. If the medication is tolerated, we monitor for 6 to 12 weeks for effect. If effective, we continue this medication indefinitely. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="bulletIndent1">SSRIs have not been tested in randomized trials of patients with ASPD; however, three small trials of impulsive aggression or anger in patients with other personality disorders have found mixed results. For example, in separate trials, treatment with <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> has led to sustained reduction in aggression, as compared with placebo, on measures of irritability and anger in individuals with borderline personality disorder [<a href="#rid33">33,34</a>]. Additionally, in a trial including 38 individuals with borderline personality disorder, six weeks of treatment with <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> led to a reduction in rapid mood shifts but no difference in impulsivity or aggression versus placebo [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/16694.html" rel="external">"Intermittent explosive disorder in adults: Treatment and prognosis", section on 'Pharmacotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong> – We occasionally use <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> for treatment of impulsive aggressive behavior in individuals with a personality disorder (including ASPD). We use lithium at doses and blood levels recommended for bipolar disorder. (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> carbonate has been found to be effective in one randomized trial [<a href="#rid36">36,37</a>]. In the trial, 66 male prison inmates with a chronic, impulsive aggressive behavior received either lithium or placebo for three months, dosed to achieve a blood level of 0.6 to 1.0 MEq per liter [<a href="#rid37">37</a>]. Individuals receiving lithium committed fewer infractions of prison rules involving threatening behavior or assaults than individuals receiving placebo. (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiseizure medications</strong> – We occasionally use antiseizure medications such as <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> or <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, at blood levels and doses recommended for bipolar disorder.</p><p></p><p class="bulletIndent1">Antiseizure medications have been found to reduce impulsive aggression in randomized trials of diverse study populations [<a href="#rid29">29,38,39</a>]. None of the studies were limited to individuals with ASPD; however, none of the trials excluded patients with personality disorders or SUDs. (See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Anticonvulsants'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis of four randomized trials found <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> to reduce aggressive behavior in patients with a history of aggression [<a href="#rid39">39</a>]. Trials were conducted in a combination of prison and community settings.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">Oxcarbazepine</a> and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, respectively, were found to reduce aggressive behavior in two randomized trials, one in a sample of patients with impulsive aggression [<a href="#rid40">40</a>] and the other with intermittent explosive disorder [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two trials of divalproex in adults with a history of aggressive behavior showed mixed results [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Propranolol</strong><strong>, </strong><strong>buspirone</strong><strong>, and trazadone</strong> – We use these medications to treat aggression in the context of ASPD in individuals brain injury or in intellectually challenged individuals [<a href="#rid42">42,43</a>].</p><p></p><p class="bulletIndent1">Response to medication has been variable; while some patients have shown improvement, others failed to improve at all. Improvement, when it has occurred, has been partial, meaning that the individual had fewer outbursts than before, or had longer periods between them.</p><p></p><p>Pharmacotherapy for emergent management of the acutely agitated, aggressive patient is discussed separately. (See  <a class="medical medical_review" href="/d/html/291.html" rel="external">"Assessment and emergency management of the acutely agitated or violent adult"</a>.)</p><p class="headingAnchor" id="H830402402"><span class="h2">Medications to avoid</span><span class="headingEndMark"> — </span>We avoid prescribing medications with potential for misuse or dependence in individuals with ASPD.</p><p>We avoid benzodiazepines in patients with ASPD due to the increased risk of addiction and risk of behavioral disinhibition. It is possible that benzodiazepines will increase aggressive outbursts and other externalizing behaviors in these patients, an adverse response that has been documented in persons with borderline personality disorder [<a href="#rid44">44</a>].</p><p>We avoid stimulant medications in individuals with ASPD with co-occurring adult attention deficit hyperactivity disorder. We typically begin treatment with non-addicting medications such as <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> or <a class="drug drug_general" data-topicid="8787" href="/d/drug information/8787.html" rel="external">atomoxetine</a> [<a href="#rid45">45</a>]. As a second-line option, stimulant medication such as <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> or <a class="drug drug_general" data-topicid="9341" href="/d/drug information/9341.html" rel="external">dextroamphetamine</a> can be prescribed in selected patients (eg, those without a history of an SUD). We monitor use of these medications closely due to their potential for abuse. We do not prescribe stimulants to patients with a current SUD, though their use can be considered for patients with a past SUD. (See  <a class="medical medical_review" href="/d/html/1232.html" rel="external">"Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p>We avoid the use of opioids to treat pain in patients with ASPD when alternative treatments are available. (See  <a class="medical medical_review" href="/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults"</a> and  <a class="medical medical_review" href="/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults"</a>.)</p><p class="headingAnchor" id="H1055579745"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122640.html" rel="external">"Society guideline links: Personality disorders"</a>.)</p><p class="headingAnchor" id="H1429506"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Our preference for treatment modality is based on symptom severity, the presence of aggressive behaviors, and the presence of co-occurring disorders. This is presented in the algorithm (<a class="graphic graphic_algorithm graphicRef139302" href="/d/graphic/139302.html" rel="external">algorithm 1</a>). (See <a class="local">'Treatment of antisocial personality disorder'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbid conditions</strong> – We address comorbid disorders (eg, mood disorders, substance use disorders, attention deficit hyperactivity disorder) as a first step in the treatment of individuals with antisocial personality disorder (ASPD). We address the comorbid disorders according to their preferred treatment method; however, we avoid treatment with medications that have an increased risk of misuse or dependence. (See <a class="local">'ASPD with comorbid disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild or moderate ASPD </strong>– For persons with mild or moderate ASPD, we suggest cognitive-behavioral therapy (CBT) rather than medication management (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). CBT may benefit those with milder forms of the disorder and those who possess some insight or have reason to improve (eg, individuals who risk losing a spouse or job due to their behavior). (See <a class="local">'Mild or moderate ASPD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For severe ASPD (psychopathy) </strong>– We do not treat individuals who have high levels of ASPD pathology (eg, psychopathy) with psychotherapy. Psychotherapy may be ineffective or even harmful when provided to persons with psychopathy or severe ASPD. However, we address comorbid disorders and aggressive behaviors as described. (See <a class="local">'Severe ASPD (psychopathy)'</a> above and <a class="local">'ASPD with comorbid disorders'</a> above and <a class="local">'Individuals with aggressive behavior'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For aggressive behavior</strong> – For individuals with ASPD and aggression who are willing to take medication, we suggest treatment with a second-generation antipsychotic medication rather than other medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Antipsychotics as first choice for aggression'</a> above.)</p><p></p><p class="bulletIndent1">Limited data support the efficacy of medication in the treatment of aggressive behavior associated with ASPD. Our preference is to try medications sequentially to avoid polypharmacy. (See <a class="local">'Individuals with aggressive behavior'</a> above and <a class="local">'Indications for medication treatment'</a> above.)</p><p></p><p class="bulletIndent1">For individuals that do not respond adequately to treatment with a second-generation antipsychotic medication, our preference is to try another second-generation antipsychotic rather than another class of medications.</p><p></p><p class="bulletIndent1">If second-generation antipsychotics are ineffective or not tolerated our preference is to try a selective serotonergic antidepressant as the next agent. Subsequent or alternative options include <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> and antiseizure medications. (See <a class="local">'Subsequent treatment for inadequate response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications to avoid</strong> – Medications with potential for misuse or dependence should be avoided in individuals with ASPD. (See <a class="local">'Medications to avoid'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">North C, Yutzy S. Goodwin &amp; Guze’s Psychiatric Diagnosis, 6th ed, Oxford University Press, New Yrok 2010.</li><li><a class="nounderline abstract_t">Robins LN, Price RK. Adult disorders predicted by childhood conduct problems: results from the NIMH Epidemiologic Catchment Area project. Psychiatry 1991; 54:116.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.</li><li class="breakAll">Black DW. Bad Boys Bad Men – Confronting Antisocial Personality Disorder, 3rd ed, Oxford University Press, 2022.</li><li><a class="nounderline abstract_t">Ullrich S, Coid J. Antisocial personality disorder: co-morbid Axis I mental disorders and health served use among a national household population. Personal Ment Health 2009; 3:151.</a></li><li><a class="nounderline abstract_t">Shapiro S, Skinner EA, Kessler LG, et al. Utilization of health and mental health services. Three Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1984; 41:971.</a></li><li><a class="nounderline abstract_t">Black DW, Braun D. Antisocial patients: a comparison of those with and those without childhood conduct disorder. Ann Clin Psychiatry 1998; 10:53.</a></li><li><a class="nounderline abstract_t">Reich JH, Green AI. Effect of personality disorders on outcome of treatment. J Nerv Ment Dis 1991; 179:74.</a></li><li><a class="nounderline abstract_t">Cacciola JS, Alterman AI, Rutherford MJ, Snider EC. Treatment response of antisocial substance abusers. J Nerv Ment Dis 1995; 183:166.</a></li><li><a class="nounderline abstract_t">Brooner RK, Kidorf M, King VL, Stoller K. Preliminary evidence of good treatment response in antisocial drug abusers. Drug Alcohol Depend 1998; 49:249.</a></li><li><a class="nounderline abstract_t">Neufeld KJ, Kidorf MS, Kolodner K, et al. A behavioral treatment for opioid-dependent patients with antisocial personality. J Subst Abuse Treat 2008; 34:101.</a></li><li><a class="nounderline abstract_t">Black DW, Simsek-Duran F, Blum N, et al. Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program? Personal Ment Health 2016; 10:205.</a></li><li><a class="nounderline abstract_t">Bateman A, O'Connell J, Lorenzini N, et al. A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. BMC Psychiatry 2016; 16:304.</a></li><li><a class="nounderline abstract_t">Wetterborg D, Dehlbom P, Långström N, et al. Dialectical Behavior Therapy for Men With Borderline Personality Disorder and Antisocial Behavior: A Clinical Trial. J Pers Disord 2020; 34:22.</a></li><li class="breakAll">National Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence (NICE), NICE Clinical Guideline 77, Antisocial Personality Disorder: Treatment, Management, and Prevention, January 2009.</li><li><a class="nounderline abstract_t">Davidson KM, Halford J, Kirkwood L, et al. CBT for violent men with antisocial personality disorder: reflections on the experience of carrying out therapy in MASCOT, a pilot randomized controlled trial. Personal Ment Health 2010; 4:86.</a></li><li class="breakAll">Beck A, Freeman A, Davis DD, et al. Antisocial personality disorder. In: Cognitive Therapy of Personality Disorders, 2nd ed, Guilford Press, New York 2004.</li><li class="breakAll">Strasburger LH. The treatment of antisocial syndromes: The therapist's feelings. In: Unmasking the Psychopath: Antisocial Personality and Related Syndromes, Reid WH, Dorr D, Walker JI, Bonner JW (Eds), WW Norton, New York 1986.</li><li><a class="nounderline abstract_t">Davidson KM, Tyrer P, Tata P, et al. Cognitive behaviour therapy for violent men with antisocial personality disorder in the community: an exploratory randomized controlled trial. Psychol Med 2009; 39:569.</a></li><li><a class="nounderline abstract_t">Gibbon S, Duggan C, Stoffers J, et al. Psychological interventions for antisocial personality disorder. Cochrane Database Syst Rev 2010; :CD007668.</a></li><li><a class="nounderline abstract_t">Davidson KM, Tyrer P. Cognitive therapy for antisocial and borderline personality disorders: single case study series. Br J Clin Psychol 1996; 35:413.</a></li><li><a class="nounderline abstract_t">Woody GE, McLellan AT, Luborsky L, O'Brien CP. Sociopathy and psychotherapy outcome. Arch Gen Psychiatry 1985; 42:1081.</a></li><li><a class="nounderline abstract_t">Huband N, McMurran M, Evans C, Duggan C. Social problem-solving plus psychoeducation for adults with personality disorder: pragmatic randomised controlled trial. Br J Psychiatry 2007; 190:307.</a></li><li><a class="nounderline abstract_t">Thylstrup B, Schrøder S, Fridell M, Hesse M. Did you get any help? A post-hoc secondary analysis of a randomized controlled trial of psychoeducation for patients with antisocial personality disorder in outpatient substance abuse treatment programs. BMC Psychiatry 2017; 17:7.</a></li><li><a class="nounderline abstract_t">Thylstrup B, Hesse M. Impulsive lifestyle counseling to prevent dropout from treatment for substance use disorders in people with antisocial personality disorder: A randomized study. Addict Behav 2016; 57:48.</a></li><li><a class="nounderline abstract_t">Gibbon S, Khalifa NR, Cheung NH, et al. Psychological interventions for antisocial personality disorder. Cochrane Database Syst Rev 2020; 9:CD007668.</a></li><li class="breakAll">Hare RD. Without conscience: The disturbing world of psychopaths among us, Pocket Books, New York 1993.</li><li class="breakAll">McCord W, McCord J. Psychopathy and delinquency, Grune and Stratton, New York 1956. p.84.</li><li><a class="nounderline abstract_t">Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol 1997; 17:341.</a></li><li><a class="nounderline abstract_t">Khalifa NR, Gibbon S, Völlm BA, et al. Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev 2020; 9:CD007667.</a></li><li><a class="nounderline abstract_t">Walker C, Thomas J, Allen TS. Treating impulsivity, irritability, and aggression of antisocial personality disorder with quetiapine. Int J Offender Ther Comp Criminol 2003; 47:556.</a></li><li><a class="nounderline abstract_t">Hirose S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci 2001; 55:161.</a></li><li><a class="nounderline abstract_t">Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54:1081.</a></li><li><a class="nounderline abstract_t">Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15:23.</a></li><li><a class="nounderline abstract_t">Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159:2048.</a></li><li><a class="nounderline abstract_t">Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology 2010; 62:43.</a></li><li><a class="nounderline abstract_t">Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133:1409.</a></li><li><a class="nounderline abstract_t">Huband N, Ferriter M, Nathan R, Jones H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev 2010; :CD003499.</a></li><li><a class="nounderline abstract_t">Jones RM, Arlidge J, Gillham R, et al. Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatry 2011; 198:93.</a></li><li><a class="nounderline abstract_t">Mattes JA. Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2005; 25:575.</a></li><li><a class="nounderline abstract_t">Stanford MS, Helfritz LE, Conklin SM, et al. A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol 2005; 13:72.</a></li><li><a class="nounderline abstract_t">Davis JM, Janicak PG, Ayd FJ. Psychopharmacotherapy of the personality disordered patients. Psychiatr Ann 1995; 25:614.</a></li><li><a class="nounderline abstract_t">Corrigan PW, Yudofsky SC, Silver JM. Pharmacological and behavioral treatments for aggressive psychiatric inpatients. Hosp Community Psychiatry 1993; 44:125.</a></li><li><a class="nounderline abstract_t">Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45:111.</a></li><li><a class="nounderline abstract_t">Westmoreland P, Gunter T, Loveless P, et al. Attention deficit hyperactivity disorder in men and women newly committed to prison: clinical characteristics, psychiatric comorbidity, and quality of life. Int J Offender Ther Comp Criminol 2010; 54:361.</a></li></ol></div><div id="topicVersionRevision">Topic 14643 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : North C, Yutzy S. Goodwin &amp; Guze’s Psychiatric Diagnosis, 6th ed, Oxford University Press, New Yrok 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1852846" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Adult disorders predicted by childhood conduct problems: results from the NIMH Epidemiologic Catchment Area project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1852846" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adult disorders predicted by childhood conduct problems: results from the NIMH Epidemiologic Catchment Area project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1852846" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Adult disorders predicted by childhood conduct problems: results from the NIMH Epidemiologic Catchment Area project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antisocial personality disorder: co-morbid Axis I mental disorders and health served use among a national household population</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6477055" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Utilization of health and mental health services. Three Epidemiologic Catchment Area sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669536" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antisocial patients: a comparison of those with and those without childhood conduct disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1990074" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of personality disorders on outcome of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7891063" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment response of antisocial substance abusers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9571389" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Preliminary evidence of good treatment response in antisocial drug abusers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17574801" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A behavioral treatment for opioid-dependent patients with antisocial personality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26671625" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27577562" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30355023" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dialectical Behavior Therapy for Men With Borderline Personality Disorder and Antisocial Behavior: A Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30355023" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dialectical Behavior Therapy for Men With Borderline Personality Disorder and Antisocial Behavior: A Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : CBT for violent men with antisocial personality disorder: reflections on the experience of carrying out therapy in MASCOT, a pilot randomized controlled trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : CBT for violent men with antisocial personality disorder: reflections on the experience of carrying out therapy in MASCOT, a pilot randomized controlled trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : CBT for violent men with antisocial personality disorder: reflections on the experience of carrying out therapy in MASCOT, a pilot randomized controlled trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18667099" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cognitive behaviour therapy for violent men with antisocial personality disorder in the community: an exploratory randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20556783" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Psychological interventions for antisocial personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8889082" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cognitive therapy for antisocial and borderline personality disorders: single case study series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4051686" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sociopathy and psychotherapy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401036" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Social problem-solving plus psychoeducation for adults with personality disorder: pragmatic randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28068951" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Did you get any help? A post-hoc secondary analysis of a randomized controlled trial of psychoeducation for patients with antisocial personality disorder in outpatient substance abuse treatment programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26882500" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Impulsive lifestyle counseling to prevent dropout from treatment for substance use disorders in people with antisocial personality disorder: A randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32880104" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Psychological interventions for antisocial personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32880104" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Psychological interventions for antisocial personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32880104" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Psychological interventions for antisocial personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9315984" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The effects of phenytoin on impulsive and premeditated aggression: a controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32880105" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pharmacological interventions for antisocial personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14526596" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Treating impulsivity, irritability, and aggression of antisocial personality disorder with quetiapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11285097" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9400343" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fluoxetine and impulsive aggressive behavior in personality-disordered subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7714224" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12450955" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453534" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lithium reduces pathological aggression and suicidality: a mini-review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/984241" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The effect of lithium on impulsive aggressive behavior in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20166067" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antiepileptics for aggression and associated impulsivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282779" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282841" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15727506" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A comparison of anticonvulsants in the treatment of impulsive aggression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Psychopharmacotherapy of the personality disordered patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432495" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pharmacological and behavioral treatments for aggressive psychiatric inpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276280" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19270267" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Attention deficit hyperactivity disorder in men and women newly committed to prison: clinical characteristics, psychiatric comorbidity, and quality of life.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
